Kisqali (Ribociclib)

Kisqali is an oral cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitor. CDK 4/6 are commonly overexpressed in breast cancer tumors, and increased CDK 4/6 activity is associated with resistance to hormone therapy. Kisqali is intended for use in combination with...